These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 33184050)
21. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151 [TBL] [Abstract][Full Text] [Related]
22. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
23. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232 [TBL] [Abstract][Full Text] [Related]
24. RhoC a new target for therapeutic vaccination against metastatic cancer. Wenandy L; Sørensen RB; Svane IM; Thor Straten P; Andersen MH Cancer Immunol Immunother; 2008 Dec; 57(12):1871-8. PubMed ID: 18415097 [TBL] [Abstract][Full Text] [Related]
25. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082 [TBL] [Abstract][Full Text] [Related]
26. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report. Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM Front Immunol; 2018; 9():2145. PubMed ID: 30283461 [No Abstract] [Full Text] [Related]
27. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Berinstein NL; Karkada M; Morse MA; Nemunaitis JJ; Chatta G; Kaufman H; Odunsi K; Nigam R; Sammatur L; MacDonald LD; Weir GM; Stanford MM; Mansour M J Transl Med; 2012 Aug; 10():156. PubMed ID: 22862954 [TBL] [Abstract][Full Text] [Related]
28. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms. Zareian N; Eremin O; Pandha H; Baird R; Kwatra V; Funingana G; Verma C; Choy D; Hargreaves S; Moghimi P; Shepherd A; Lobo DN; Eremin J; Farzaneh F; Kordasti S; Spicer J Exp Biol Med (Maywood); 2024; 249():10021. PubMed ID: 38463391 [TBL] [Abstract][Full Text] [Related]
29. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887 [TBL] [Abstract][Full Text] [Related]
30. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821 [TBL] [Abstract][Full Text] [Related]
31. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952 [TBL] [Abstract][Full Text] [Related]
32. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452 [TBL] [Abstract][Full Text] [Related]
33. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154 [TBL] [Abstract][Full Text] [Related]
34. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM Front Immunol; 2020; 11():572172. PubMed ID: 33324397 [TBL] [Abstract][Full Text] [Related]
35. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509 [TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study. Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804 [TBL] [Abstract][Full Text] [Related]
37. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022 [TBL] [Abstract][Full Text] [Related]
38. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618 [TBL] [Abstract][Full Text] [Related]
39. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Meidenbauer N; Harris DT; Spitler LE; Whiteside TL Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524 [TBL] [Abstract][Full Text] [Related]
40. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]